| Literature DB >> 21746752 |
Karen D Ersche1, Paul Cumming, Kevin J Craig, Ulrich Müller, Naomi A Fineberg, Edward T Bullmore, Trevor W Robbins.
Abstract
We report about a clinical observation in a well-characterized group of patients with obsessive-compulsive disorder (OCD) during an experimental medicine study in which a single dose of amisulpride (a selective D₂/₃ antagonist) was administered. Almost half of the OCD patients, in particular those with less severe obsessive-compulsive symptoms, experienced acute akathisia in response to the amisulpride challenge. This unexpectedly high incidence of akathisia in the selective serotonin reuptake inhibitor (SSRI)-treated patients with OCD suggests that individual differences in dopamine-serotonin interactions underlie the clinical heterogeneity of OCD, and may thus explain the insufficiency of SSRI monotherapy in those patients not experiencing a satisfactory outcome in symptom reduction. We further speculate about the neuropathology possibly underlying this clinical observation and outline a testable hypothesis for future molecular imaging studies.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21746752 PMCID: PMC3664784 DOI: 10.1177/0269881111405363
Source DB: PubMed Journal: J Psychopharmacol ISSN: 0269-8811 Impact factor: 4.153